Scientists develop new natural killer cell strategy to target HIV
Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have successfully identified a new approach using ...
Antibody therapy shrinks immunotherapy-resistant lung cancer tumors in mice
An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s ...
Monthly Prescribing Reference6d
Troculeucel Gets Fast Track Status for Moderate Alzheimer Disease
The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.
Baylor College of Medicine1d
Long-term survival following CAR T cell therapy to treat neuroblastoma
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
Life Science Leader13d
Companies To Watch: Senti Bio
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...